Mersana Therapeutics, Inc.
MRSN
$0.385
-$0.015-3.75%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 9.88% | -14.70% | -22.68% | 18.40% | 38.65% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.88% | -14.70% | -22.68% | 18.40% | 38.65% |
| Cost of Revenue | -50.75% | -58.12% | -54.33% | -35.26% | -14.49% |
| Gross Profit | 70.81% | 71.60% | 62.29% | 46.64% | 24.11% |
| SG&A Expenses | -31.46% | -34.50% | -31.57% | -15.57% | 4.53% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -45.22% | -51.71% | -48.53% | -30.28% | -9.78% |
| Operating Income | 57.10% | 59.43% | 53.08% | 37.61% | 16.10% |
| Income Before Tax | 59.94% | 62.34% | 51.31% | 36.74% | 15.94% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 59.69% | 62.13% | 51.31% | 36.74% | 15.94% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 59.69% | 62.13% | 51.31% | 36.74% | 15.94% |
| EBIT | 57.10% | 59.43% | 53.08% | 37.61% | 16.10% |
| EBITDA | 57.68% | 60.01% | 53.62% | 38.06% | 16.47% |
| EPS Basic | 62.31% | 65.62% | 57.80% | 46.52% | 31.64% |
| Normalized Basic EPS | 60.65% | 64.69% | 61.32% | 49.92% | 34.93% |
| EPS Diluted | 62.25% | 65.56% | 57.76% | 46.48% | 31.64% |
| Normalized Diluted EPS | 60.65% | 64.69% | 61.32% | 49.92% | 34.93% |
| Average Basic Shares Outstanding | 5.58% | 9.57% | 14.99% | 18.97% | 24.02% |
| Average Diluted Shares Outstanding | 5.58% | 9.57% | 14.99% | 18.97% | 24.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |